Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma

Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma

Abstract Background Antibodies targeting the programmed cell death-1 (PD-1)/PD-ligand 1 (PD-1/PD-L1) checkpoint have shown promising clinical activity in patients with advanced urothelial carcinoma (UC). Expression of PD-L1 in UC tumors has been investigated using different antibody clones, staining...

Full description

Bibliographic Details
Main Authors: Magdalena Zajac, Marietta Scott, Marianne Ratcliffe, Paul Scorer, Craig Barker, Hytham Al-Masri, Marlon C. Rebelatto, Jill Walker
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Diagnostic Pathology
Subjects:
PD-L1
Urothelial carcinoma
Assay
VENTANA PD-L1 SP263
Online Access:http://link.springer.com/article/10.1186/s13000-019-0873-6

Internet

http://link.springer.com/article/10.1186/s13000-019-0873-6

Similar Items